New combo therapy aims to boost survival in esophageal cancer patients

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer who have not had prior treatment will be randomly assigned to receive either the new combination or standard treatment alone. The main goal is to see if the combination improves overall survival.